Goldman Sachs invests in BenevolentAI

BenevolentAI is pleased to announce that, in an extension to its recent fundraising reported on 19 April 2018, Goldman Sachs has invested in the company.

Joanna Shields, Chief Executive Officer of BenevolentAI commented: “We are thrilled to have Goldman Sachs on board and supporting us in our mission to transform the way breakthrough medicines are discovered and developed.”


About BenevolentAI

BenevolentAI aims to accelerate the journey from data to better medicines.  As the world’s only AI company with end-to-end capability from early discovery to late stage clinical development, Benevolent’s technology platform was built to mine new knowledge from vast quantities of biomedical data and make it available to its world leading scientists in order to bring new treatments to patients faster.

The Benevolent Platform is designed to find new ways to treat disease through target identification, develop the most effective medicines with molecular design, and then understand how individual patients will respond to treatment via clinical mechanistic stratification.  It is a truly integrated data and technology-driven approach to drug development, based on systems and scientists that learn through each experimental loop to generate more effective treatments and new insights into the underlying causes of disease.

>>> Read Ken Mulvany’s blog titled Funding Fundamental Change



Please contact

Goldman Sachs invests in BenevolentAI